



GW9662

Catalog No: tcsc1102

Available Sizes
Size: 5mg
Size: 10mg
Size: 25mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 22978-25-2
Formula: C ₁₃ H ₉ CIN ₂ O ₃
Pathway: Cell Cycle/DNA Damage
Target: PPAR
Purity / Grade: >98%
Solubility: DMSO : ≥ 100 mg/mL (361.43 mM); H2O :
Observed Molecular Weight:



Product Description

GW9662 is a potent and selective **PPAR** γ antagonist with an **IC**₅₀ of 3.3 nM, showing 10 and 1000-fold selectivity over PPAR α and PPAR α , respectively.

IC50 & Target: IC50: 3.3 nM/32 nM/2 μ M (PPAR $\gamma/\alpha/\delta$)^[1]

In Vitro: GW9662 inhibits radioligand binding to PPARγ, PPARα, and PPARδ with pIC $_{50}$ s of 8.48±0.27 (IC $_{50}$ =3.3 nM; n=10), 7.49±0.17 (IC $_{50}$ =32 nM; n=9), and 5.69±0.17 (IC $_{50}$ =2000 nM; n=3), respectively. GW9662 has nanomolar IC $_{50}$ versus PPARγ and is 10- and 600-fold less potent in binding experiments using PPARα and PPARδ, respectively. In cell-based reporter assays, GW9662 is a potent and selective antagonist of full-length PPARγ $^{[1]}$. Co-treatment with both 50 μM Rosiglitazone and 10 μM GW9662 results in statistically lower viable cell numbers after 7 days when compared to treatment with either 50 μM rosiglitazone (P=0.001) or 10 μM GW9662 (P=0.01) alone $^{[2]}$.

In Vivo: Bone marrow (BM) nucleated cell counts in both BADGE- and GW9662(1 mg/kg, i.p.)-treated mice are significantly higher than counts in the aplastic anemia (AA) group^[3]. GW9662 (1 mg/kg, i.p.) largely attenuates the renoprotective effects of Lipopolysaccharide (LPS) in the rat^[4].

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!